The monocolonal anti-body, the second novel biological drug developed entirely in India, is an anti-CD6 antibody based product. Biocon’s Alzumab is the first anti-CD6 monoclonal antibody to be commercialized, an outcome of path breaking research in India, said Biocon’s CMD, Kiran Mazumdar-Shaw, while launching the product in Bangalore on August 10. A patient has to take 28 injections and 12 maintenance shots every alternate weeks over 24 weeks. Colorcon opens new lab in China. BANGALORE: Biotechnology firm Biocon rolled out its first biologic drug for the treatment of auto-immune disease psoriasis on Saturday. In 2006, the company had launched BIOMAb EGFR, to treat head and neck cancer. Today, Biocon has evolved from an enzyme company to a fully integrated biopharmaceutical company. 11 billion, making Biocon only the second Indian company to cross the 1 billion mark on the first day of listing; Syngene establishes new research centre; Biocon launches INSUGEN; Biocon enhances Partnership with Mylan through Strategic Collaboration for Insulin Products Biocon Delivers a Healthy Growth of 22 driven by strong traction in Biopharma Biocon Launched ALZUMAb – a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India.
10: Bangalore-based Biocon today announced the launch of a biologic researched, developed and manufactured in the country to treat chronic plaque psoriasis. A biologic is a drug composed of sugar, proteins and living entities such as cells and tissues. Sources from Biocon told The Telegraph that a vial would cost around Rs 7,950. Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes, heart disease and depression, according to the US National Foundation of Psoriasis. On 10 August, Biocon announced the launch in India of Alzumab for treatment of psoriasis, saying it would come with a less aggressive dosing regimen and a longer treatment-free period, promising a better quality of life to the patient. The biologic drug, which will soon be tested on patients with rheumatoid arthritis, can be applied to over 100 different types of auto-immune diseases including Type 1 diabetes and multiple sclerosis. She started the company in a rented garage in Bangalore with a seed capital of Rs.10,000. Biocon, the Bangalore-based biotech company, launched a novel biologic Alzumab (itolizumab) for chronic plaque psoriasis onto the Indian market this summer, riding a wave of high expectations. Alzumab, a humanized IgG1 mAb, was approved by the Drugs Controller General of India in January 2013 and launched in August.
Bangalore-based Biocon announced the launch of a biologic which has been researched, developed and manufactured in the country to treat chronic plaque psoriasis. ‘This new line of treatment will usher in a paradigm shift in the management of psoriasis. The company believes that Alzumab will be safer and more effective than existing therapies, have no side effects and will prevent the disease from recurring. Most people with psoriasis have thick, reddened skin with flaky, silvery patches called scales. Kiran Mazumdar-Shaw wants the biotech company to break into the 1-billion club by 2018. With the launch of its novel biological psoriasis drug Alzumab in 2013 and its biosimilar breast cancer drug early this year, Biocon has made it clear that it is a determined and hungry player in the competitive pharmaceutical industry. The 1,400-bed MSCC functions as a for-profit business for those who can afford treatment; patients from low-income families get subsidised or free care. We need to understand cancer at the immune level, says Mazumdar-Shaw, who has partnered with Bangalore-based silico-tech company Strand Life Sciences to develop low-cost genetic markers that can predict whether a person will develop cancer, as well as identify the gene responsible for it. Prithvi Pankaj Shaw: 10 things to know about the top scorer in Harris Shield. Alzumab, now commercially available in the country for treating patients with chronic plaque psoriasis, was priced at least 50 per cent lower than similar drugs in the market, the company’s chairperson and managing director, Kiran Mazumdar-Shaw told a news conference here. Biotechnology major Biocon plans to launch in July its novel biologic drug Itolizumab branded as ‘Alzumab’ to be used for the treatment of chronic plaque psoriasis in the country.
New Drug Makes Biocon Upbeat
Biocon, Asia’s largest biotechnology company, started itself with seed capital of Rs.10, 000 in 1978, is now a billion dollar company. Biocon Limited is an Indian Biopharmaceutical giant based in Bangalore. Here you can find some recent developments and company vacancies (as mentioned in their job site). Following are vacancies for India and Bangalore R&D center of Biocon. Biocon on 10th August 2013 launched a new drug as a cure for Psoriasis. It is of biological origin Target: CD6 Cells Mode of Action: Attaches to CD6 cells and turns down T cell activation. Earlier this month, Bangalore-based Biocon, one of the country’s leading biotechnology firms, launched an innovative biologic drug called Alzumab for the treatment of an auto-immune ailment, psoriasis. Latest News. During the past 30 years the biotech industry has launched more than 100 molecules1, 2, improving the quality of life of millions of people. The revenues for specific biotech drugs were obtained from company 10-K filings, investor relation departments of specific companies, investor websites (e. Humira, with advantages of better dosing and being the only fully human mAb in a crowded anti-tumor necrosis factor (TNF)-alpha field, has been gaining most of the new patient share in rheumatoid arthritis and Crohn’s disease. With these two launches, Biocon has again proved to the world that as far as scientific talent is concerned Indians are second to none. To meet increasing demand, Biocon had enhanced its insulin manufacturing capacity in Bangalore in FY14. 678910 She is on the Financial Times’ top 50 women in business list.